Related Experiment Video
Updated: Jun 5, 2025

Adeno-Associated Virus-Mediated Delivery of CRISPR for Cardiac Gene Editing in Mice
Published on: August 2, 2018
Management of Cardiac Involvement in Becker Muscular Dystrophy: A Case Report
Taulant Gishto1, Silvia Methoxha1, Naltin Shuka2
1Cardiovascular Disease, University Hospital Center "Mother Teresa", Tirana, ALB.
Insights
Becker muscular dystrophy (BMD) patients can experience severe heart problems. This case highlights successful management of ventricular arrhythmia and heart failure with an ICD and guideline-directed medical therapy.
Area of Science:
- Cardiology
- Neurology
- Genetics
Background:
- Becker muscular dystrophy (BMD) is an X-linked recessive disorder affecting dystrophin, frequently leading to cardiac complications.
- Cardiac manifestations in BMD range from asymptomatic involvement to severe heart failure and cardiomyopathy.
Observation:
- A 32-year-old BMD patient presented with palpitations, dyspnea, fatigue, and weakness.
- Holter monitoring revealed complex ventricular arrhythmia, and echocardiography showed severe left ventricular systolic dysfunction (LVEF 23%).
Findings:
- An implantable cardioverter defibrillator (ICD) was implanted.
- Guideline-directed medical therapy (GDMT) including sacubitril/valsartan, bisoprolol, furosemide, spironolactone, and dapagliflozin was initiated.
Implications:
- The patient showed clinical improvement post-discharge, with reduced dyspnea.
- This case underscores the importance of multidisciplinary management for cardiac issues in BMD patients.
- Regular follow-up is crucial to monitor therapeutic effectiveness and cardiac function.
Abstract:
Becker muscular dystrophy (BMD) is an X-linked recessive neuromuscular disorder caused by a mutation in the dystrophin gene. Cardiac involvement is a frequent finding in BMD, and manifestations may vary from asymptomatic cardiac involvement to developing symptoms of heart failure and severe cardiomyopathy. We presented the case of a 32-year-old wheelchair-dependent BMD patient who came to our cardiology clinic with a two-month history of heart palpitations, rest and nocturnal dyspnea, fatigue, and generalized muscular weakness. Upon evaluation, a 24-hour Holter rhythm showed complex ventricular arrhythmia and 300 polymorphic ventricular extrasystoles with episodes of ventricular bigeminy, while echocardiography revealed a dilated left ventricle with severe systolic dysfunction (left ventricular ejection fraction (LVEF) 23%) and impaired global contractility. An implantable cardioverter defibrillator (ICD) was implanted, and guideline direct medical therapy (GDMT), sacubitril/valsartan, bisoprolol, furosemide, spironolactone, and dapagliflozin were initiated. The patient was discharged five days later, in an improved clinical condition, without dyspnea. A follow-up appointment two weeks after discharge was recommended in order to evaluate the patient's symptoms and the effectiveness of GDMT and a follow-up echocardiography at least three months after discharge to evaluate the heart's systolic and diastolic function.
More Related Videos
08:13Purification and Transplantation of Myogenic Progenitor Cell Derived Exosomes to Improve Cardiac Function in Duchenne Muscular Dystrophic Mice
Published on: April 10, 2019
09:18Measurements of Motor Function and Other Clinical Outcome Parameters in Ambulant Children with Duchenne Muscular Dystrophy
Published on: January 12, 2019
Related Concept Videos
Myocarditis III: Medical Management
Rheumatic Heart Disease III: Medical Management
Myocarditis IV: Nursing Management
Satellite Stem Cells and Muscular Dystrophy
Myasthenia Gravis: Overview and Treatment
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
Mitral Valve Prolapse II: Assessment and Management